Artwork

Innehåll tillhandahållet av Dr. Jason Edwards. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Dr. Jason Edwards eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !

Revolutionary Advancements in Blood Cancer Treatment with Dr. Mark Fesler

30:40
 
Dela
 

Manage episode 439356417 series 3599583
Innehåll tillhandahållet av Dr. Jason Edwards. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Dr. Jason Edwards eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.

Discover the revolutionary advancements in blood cancer treatment with Dr. Mark Fesler, a leading hematologist and oncologist at St. Luke's. We promise you'll gain a comprehensive understanding of the intricate phases of clinical trials, from safety assessments to efficacy evaluations. Dr. Fesler sheds light on the transformative shift from traditional cytotoxic drugs to cutting-edge immunotherapies, including checkpoint inhibitors, chimeric antigen T cells, and the promising bispecific antibodies that are changing the landscape of cancer care.
Navigate the complexities of clinical trials through the lens of Nassim Nicholas Taleb's "Black Swan" concept, appreciating the delicate balance of risk and benefit in drug development. We'll uncover the significant breakthroughs in bispecific antibodies for blood cancers and discuss the ethical considerations of fast-tracking treatments for patients facing limited life expectancy. Additionally, we tackle the reproducibility crisis in clinical trials, highlighting the importance of reliable and robust findings in ensuring patient safety and treatment efficacy.
Look to the future as we explore the expanding potential of bispecific therapies beyond blood cancers to solid tumors like breast, prostate, and lung cancer. Dr. Fesler shares insights on ongoing clinical trials at St. Luke's and emphasizes the move towards outpatient treatments and earlier lines of therapy. Learn about the specific immune-related cancers that show promising responses to these therapies and find out how patients can get involved in these groundbreaking studies. Join us in celebrating the relentless efforts of healthcare professionals and researchers driving innovation and improving patient outcomes in hematology and oncology.

  continue reading

Kapitel

1. Advancements in Blood Cancer Treatment (00:00:00)

2. Risks and Benefits in Clinical Trials (00:11:21)

3. Expanding Use of Bispecific Therapies (00:22:29)

4. Advancing Hematology and Oncology (00:29:29)

12 episoder

Artwork
iconDela
 
Manage episode 439356417 series 3599583
Innehåll tillhandahållet av Dr. Jason Edwards. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Dr. Jason Edwards eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.

Discover the revolutionary advancements in blood cancer treatment with Dr. Mark Fesler, a leading hematologist and oncologist at St. Luke's. We promise you'll gain a comprehensive understanding of the intricate phases of clinical trials, from safety assessments to efficacy evaluations. Dr. Fesler sheds light on the transformative shift from traditional cytotoxic drugs to cutting-edge immunotherapies, including checkpoint inhibitors, chimeric antigen T cells, and the promising bispecific antibodies that are changing the landscape of cancer care.
Navigate the complexities of clinical trials through the lens of Nassim Nicholas Taleb's "Black Swan" concept, appreciating the delicate balance of risk and benefit in drug development. We'll uncover the significant breakthroughs in bispecific antibodies for blood cancers and discuss the ethical considerations of fast-tracking treatments for patients facing limited life expectancy. Additionally, we tackle the reproducibility crisis in clinical trials, highlighting the importance of reliable and robust findings in ensuring patient safety and treatment efficacy.
Look to the future as we explore the expanding potential of bispecific therapies beyond blood cancers to solid tumors like breast, prostate, and lung cancer. Dr. Fesler shares insights on ongoing clinical trials at St. Luke's and emphasizes the move towards outpatient treatments and earlier lines of therapy. Learn about the specific immune-related cancers that show promising responses to these therapies and find out how patients can get involved in these groundbreaking studies. Join us in celebrating the relentless efforts of healthcare professionals and researchers driving innovation and improving patient outcomes in hematology and oncology.

  continue reading

Kapitel

1. Advancements in Blood Cancer Treatment (00:00:00)

2. Risks and Benefits in Clinical Trials (00:11:21)

3. Expanding Use of Bispecific Therapies (00:22:29)

4. Advancing Hematology and Oncology (00:29:29)

12 episoder

Alla avsnitt

×
 
Loading …

Välkommen till Player FM

Player FM scannar webben för högkvalitativa podcasts för dig att njuta av nu direkt. Den är den bästa podcast-appen och den fungerar med Android, Iphone och webben. Bli medlem för att synka prenumerationer mellan enheter.

 

Snabbguide